Abstract:The human complement pathway plays a pivotal role in immune defence, homeostasis, and autoimmunity regulation, and complement-based therapeutics have emerged as promising interventions, with both antagonistic and agonistic approaches being explored. The classical pathway of complement is initiated when the C1 complex binds to hexameric antibody platforms. Recent structural data revealed that C1 binds to small, homogeneous interfaces at the periphery of the antibody platforms. Here, we have developed a novel strategy for complement activation using macrocyclic peptides designed to mimic the interface between antibodies and the C1 complex. In vitro selection utilizing the RaPID system identified a cyclic peptide (cL3) that binds to the C1 complex via the globular head domains of C1q. Notably, when immobilized on surfaces, cL3 effectively recruits C1 from human serum, activates C1s proteases, and induces lysis of cell-mimetic lipid membranes. This represents the first instance of a peptide capable of activating complement by binding C1 when immobilized. Further characterization and synthesis of deletion mutants revealed a critical cycle size of cL3 essential for C1 binding and efficient complement activation. Importantly, cL3 also demonstrated the ability to inhibit complement-mediated lysis without affecting C1 binding, highlighting its potential as a therapeutic modality to prevent complement-dependent cytotoxicity whilst promoting cellular phagocytosis and cell clearance. In summary, this study introduces the concept of "Peptactins" - peptide-based activators of complement - and underscores the potential of macrocyclic peptides for complement modulation, offering potential advantages over traditional biologicals in terms of size, production, and administration.

DNA Nanostructure-Templated Antibody Complexes Provide Insights into the Geometric Requirements of Human Complement Cascade Activation

Complement Is Activated by IgG Hexamers Assembled at the Cell Surface

Complement activation by IgG subclasses is governed by their ability to oligomerize upon antigen binding

The Solvent at Antigen-Binding Site Regulated C3d-CR2 Interactions Through the C-terminal Tail of C3d at Different Ion Strengths: Insights from Molecular Dynamics Simulation.

Designed proteins assemble antibodies into modular nanocages

Structural analysis of the human C5a-C5aR1 complex using cryo-electron microscopy

Interaction Studies of Hexameric and Pentameric IgMs with Serum-Derived C1q and Recombinant C1q Mimetics

Structural evaluation of a nanobody targeting complement receptor Vsig4 and its cross reactivity

Selection and characterization of a peptide-based complement modulator targeting C1 of the innate immune system

Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped During Glycan Biosynthesis

Antibody CDR loops as ensembles in solution vs. canonical clusters from X-ray structures

Experimental Structures of Antibody/MHC-I Complexes Reveal Details of Epitopes Overlooked by Computational Prediction

Nanoparticle-Binding Immunoglobulins Predict Variable Complement Responses in Healthy and Diseased Cohorts

Molecular basis of anaphylatoxin binding, activation, and signaling bias at complement receptors

Reconstitution of the alternative pathway of the complement system enables rapid delineation of the mechanism of action of novel inhibitors

Modeling antigen-antibody nanoparticle bioconjugates and their polymorphs

Cryo-EM analysis of complement C3 reveals a reversible major opening of the macroglobulin ring

De Novo Synthesis and Structural Elucidation of CDR-H3 Loop Mimics

Agnostic B cell selection approach identifies antibodies against K. pneumoniae that synergistically drive complement activation

Artificial Antibody Created by Conformational Reconstruction of the Complementary-Determining Region on Gold Nanoparticles.

DNA Nanotechnology for Investigating Mechanical Signaling in the Immune System